Global Viral Vector-Based Gene Therapy Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030

1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Classification of Viral Vector-Based Gene Therapy Drugs by Type
  • 1.3.1 Overview: Global Viral Vector-Based Gene Therapy Drugs Market Size by Type: 2019 Versus 2023 Versus 2030
  • 1.3.2 Global Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type in 2023
  • 1.3.3 Retroviral Vector
  • 1.3.4 Adenovirus Vector
  • 1.3.5 Lentiviral Vector
  • 1.3.6 Others
• 1.4 Global Viral Vector-Based Gene Therapy Drugs Market by Application
  • 1.4.1 Overview: Global Viral Vector-Based Gene Therapy Drugs Market Size by Application: 2019 Versus 2023 Versus 2030
  • 1.4.2 Hospital
  • 1.4.3 Diagnostic and Testing Laboratories
  • 1.4.4 Academic and Research Organizations
  • 1.4.5 Others
• 1.5 Global Viral Vector-Based Gene Therapy Drugs Market Size & Forecast
• 1.6 Global Viral Vector-Based Gene Therapy Drugs Market Size and Forecast by Region
  • 1.6.1 Global Viral Vector-Based Gene Therapy Drugs Market Size by Region: 2019 VS 2023 VS 2030
  • 1.6.2 Global Viral Vector-Based Gene Therapy Drugs Market Size by Region, (2019-2030)
  • 1.6.3 North America Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
  • 1.6.4 Europe Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
  • 1.6.5 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
  • 1.6.6 South America Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
  • 1.6.7 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)

2 Company Profiles

• 2.1 GSK
  • 2.1.1 GSK Details
  • 2.1.2 GSK Major Business
  • 2.1.3 GSK Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.1.4 GSK Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.1.5 GSK Recent Developments and Future Plans
• 2.2 MolMed
  • 2.2.1 MolMed Details
  • 2.2.2 MolMed Major Business
  • 2.2.3 MolMed Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.2.4 MolMed Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.2.5 MolMed Recent Developments and Future Plans
• 2.3 GILD
  • 2.3.1 GILD Details
  • 2.3.2 GILD Major Business
  • 2.3.3 GILD Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.3.4 GILD Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.3.5 GILD Recent Developments and Future Plans
• 2.4 JW Therapeutics
  • 2.4.1 JW Therapeutics Details
  • 2.4.2 JW Therapeutics Major Business
  • 2.4.3 JW Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.4.4 JW Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.4.5 JW Therapeutics Recent Developments and Future Plans
• 2.5 Sibiono
  • 2.5.1 Sibiono Details
  • 2.5.2 Sibiono Major Business
  • 2.5.3 Sibiono Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.5.4 Sibiono Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.5.5 Sibiono Recent Developments and Future Plans
• 2.6 Latima
  • 2.6.1 Latima Details
  • 2.6.2 Latima Major Business
  • 2.6.3 Latima Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.6.4 Latima Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.6.5 Latima Recent Developments and Future Plans
• 2.7 Novartis
  • 2.7.1 Novartis Details
  • 2.7.2 Novartis Major Business
  • 2.7.3 Novartis Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.7.4 Novartis Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.7.5 Novartis Recent Developments and Future Plans
• 2.8 Bluebird Bio
  • 2.8.1 Bluebird Bio Details
  • 2.8.2 Bluebird Bio Major Business
  • 2.8.3 Bluebird Bio Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.8.4 Bluebird Bio Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.8.5 Bluebird Bio Recent Developments and Future Plans
• 2.9 Thermo Fisher Scientific
  • 2.9.1 Thermo Fisher Scientific Details
  • 2.9.2 Thermo Fisher Scientific Major Business
  • 2.9.3 Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.9.4 Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.9.5 Thermo Fisher Scientific Recent Developments and Future Plans
• 2.10 Intas
  • 2.10.1 Intas Details
  • 2.10.2 Intas Major Business
  • 2.10.3 Intas Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.10.4 Intas Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.10.5 Intas Recent Developments and Future Plans
• 2.11 BMS
  • 2.11.1 BMS Details
  • 2.11.2 BMS Major Business
  • 2.11.3 BMS Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.11.4 BMS Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.11.5 BMS Recent Developments and Future Plans
• 2.12 Orchard Therapeutics
  • 2.12.1 Orchard Therapeutics Details
  • 2.12.2 Orchard Therapeutics Major Business
  • 2.12.3 Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.12.4 Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.12.5 Orchard Therapeutics Recent Developments and Future Plans
• 2.13 Shanghai Sunway Biotech
  • 2.13.1 Shanghai Sunway Biotech Details
  • 2.13.2 Shanghai Sunway Biotech Major Business
  • 2.13.3 Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.13.4 Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.13.5 Shanghai Sunway Biotech Recent Developments and Future Plans
• 2.14 uniQure
  • 2.14.1 uniQure Details
  • 2.14.2 uniQure Major Business
  • 2.14.3 uniQure Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.14.4 uniQure Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.14.5 uniQure Recent Developments and Future Plans
• 2.15 Spark Therapeutics
  • 2.15.1 Spark Therapeutics Details
  • 2.15.2 Spark Therapeutics Major Business
  • 2.15.3 Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
  • 2.15.4 Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.15.5 Spark Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players

• 3.1 Global Viral Vector-Based Gene Therapy Drugs Revenue and Share by Players (2019-2024)
• 3.2 Market Share Analysis (2023)
  • 3.2.1 Market Share of Viral Vector-Based Gene Therapy Drugs by Company Revenue
  • 3.2.2 Top 3 Viral Vector-Based Gene Therapy Drugs Players Market Share in 2023
  • 3.2.3 Top 6 Viral Vector-Based Gene Therapy Drugs Players Market Share in 2023
• 3.3 Viral Vector-Based Gene Therapy Drugs Market: Overall Company Footprint Analysis
  • 3.3.1 Viral Vector-Based Gene Therapy Drugs Market: Region Footprint
  • 3.3.2 Viral Vector-Based Gene Therapy Drugs Market: Company Product Type Footprint
  • 3.3.3 Viral Vector-Based Gene Therapy Drugs Market: Company Product Application Footprint
• 3.4 New Market Entrants and Barriers to Market Entry
• 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

• 4.1 Global Viral Vector-Based Gene Therapy Drugs Consumption Value and Market Share by Type (2019-2024)
• 4.2 Global Viral Vector-Based Gene Therapy Drugs Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

• 5.1 Global Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application (2019-2024)
• 5.2 Global Viral Vector-Based Gene Therapy Drugs Market Forecast by Application (2025-2030)

6 North America

• 6.1 North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
• 6.2 North America Viral Vector-Based Gene Therapy Drugs Market Size by Application (2019-2030)
• 6.3 North America Viral Vector-Based Gene Therapy Drugs Market Size by Country
  • 6.3.1 North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2030)
  • 6.3.2 United States Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 6.3.3 Canada Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 6.3.4 Mexico Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)

7 Europe

• 7.1 Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
• 7.2 Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2030)
• 7.3 Europe Viral Vector-Based Gene Therapy Drugs Market Size by Country
  • 7.3.1 Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2030)
  • 7.3.2 Germany Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 7.3.3 France Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 7.3.4 United Kingdom Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 7.3.5 Russia Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 7.3.6 Italy Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)

8 Asia-Pacific

• 8.1 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
• 8.2 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2030)
• 8.3 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size by Region
  • 8.3.1 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Region (2019-2030)
  • 8.3.2 China Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 8.3.3 Japan Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 8.3.4 South Korea Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 8.3.5 India Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 8.3.6 Southeast Asia Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 8.3.7 Australia Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)

9 South America

• 9.1 South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
• 9.2 South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2030)
• 9.3 South America Viral Vector-Based Gene Therapy Drugs Market Size by Country
  • 9.3.1 South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2030)
  • 9.3.2 Brazil Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 9.3.3 Argentina Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)

10 Middle East & Africa

• 10.1 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
• 10.2 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2030)
• 10.3 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size by Country
  • 10.3.1 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2030)
  • 10.3.2 Turkey Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 10.3.3 Saudi Arabia Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
  • 10.3.4 UAE Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)

11 Market Dynamics

• 11.1 Viral Vector-Based Gene Therapy Drugs Market Drivers
• 11.2 Viral Vector-Based Gene Therapy Drugs Market Restraints
• 11.3 Viral Vector-Based Gene Therapy Drugs Trends Analysis
• 11.4 Porters Five Forces Analysis
  • 11.4.1 Threat of New Entrants
  • 11.4.2 Bargaining Power of Suppliers
  • 11.4.3 Bargaining Power of Buyers
  • 11.4.4 Threat of Substitutes
  • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

• 12.1 Viral Vector-Based Gene Therapy Drugs Industry Chain
• 12.2 Viral Vector-Based Gene Therapy Drugs Upstream Analysis
• 12.3 Viral Vector-Based Gene Therapy Drugs Midstream Analysis
• 12.4 Viral Vector-Based Gene Therapy Drugs Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology
• 14.2 Research Process and Data Source